Casting a dark cloud over Memorial Day weekend for Pozen Inc. was word the Friday before from the FDA that its second migraine drug is not approvable. But Wall Street's thunder was not heard until Tuesday, when Pozen disclosed the news and saw more than 37 percent of its stock value wash away. Read More
